Trial · NCT02704403
Results by group76
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 76
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis | 120 mg Elafibranor | 138 | Participants | ||
| Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis | Placebo | 52 | Participants | ||
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | Baseline / Events | 0 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | Baseline / Events | 0 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | Baseline / Censored | 0 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | Baseline / Censored | 0 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | Baseline / No events or not censored | 1437 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | Baseline / No events or not censored | 720 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | 6 months / Events | 1 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | 6 months / Events | 1 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | 6 months / Censored | 48 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | 6 months / Censored | 26 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | 6 months / No events or not censored | 1388 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | 6 months / No events or not censored | 693 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | 12 months / Events | 1 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | 12 months / Events | 1 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | 12 months / Censored | 159 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | 12 months / Censored | 82 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | 120 mg Elafibranor | 12 months / No events or not censored | 1277 | Participants | |
| Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes | Placebo | 12 months / No events or not censored | 637 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02704403/results